Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
CRISPR Therapeutics makes gene-editing medicines that change a patient's DNA to treat serious diseases.
CRISPR Therapeutics is a biotech company that edits genes — the instruction manuals inside your cells — to treat serious diseases. Its main tool is CRISPR, a kind of molecular scissors that can cut DNA at a precise spot, letting scientists switch a faulty gene off or fix it. The company's biggest win so far is Casgevy, a one-time treatment for sickle cell disease and beta thalassemia, two painful inherited blood disorders. Casgevy was the first CRISPR-based medicine approved anywhere in the world, cleared in the UK in late 2023 and in the US shortly after.
Casgevy works by taking a patient's own blood stem cells out of the body, editing them so they produce healthy red blood cells, and putting them back. It is a genuine cure-like treatment, but the logistics are brutal: it involves chemotherapy, weeks in a hospital, and a price around $2 million per patient. That high price and heavy process limit how many people can actually get it. The drug is partnered with Vertex Pharmaceuticals, which handles much of the commercialization, and CRISPR Therapeutics shares in the profits. The company does not really sell products itself yet — it earns money mainly through collaboration payments, milestone fees, and its share of Casgevy profits, with research spending funded by a strong cash pile. It is also testing gene editing in other areas, including immuno-oncology and autoimmune disease, where early data has shown promise. Cash burn is the constant concern: these programs are expensive, take years, and can fail at any stage.
In 2013, Emmanuelle Charpentier and two partners started a company to turn a huge lab discovery into medicine. A year earlier, she had co-written the paper showing that CRISPR/Cas9 could cut and edit DNA, a tool that worked like molecular scissors. The company's whole bet was that those scissors could be aimed at the root cause of genetic diseases. They called it Inception Genomics AG.
The following year, the company took its official name, CRISPR Therapeutics AG, putting the science right in the title. It was a clear signal that this was a pure gene editing company, not a general biotech.
In 2015, the young company teamed up with Vertex Pharmaceuticals to hunt for CRISPR-based treatments for genetic diseases. That partnership produced the program that would come to define the company's future: CTX001, a therapy built on editing a patient's own blood cells. For a small startup, having a big partner helped carry the science toward real patients.
In 2016, the company sold shares to the public for the first time. The money raised gave it the long runway that gene editing research needs, and it turned a scrappy startup into a public biotech with all the scrutiny that brings.
Samarth Kulkarni had joined in 2015 to run business dealings. In 2017, he became CEO, and later he would also take the chairman's seat. His rise marked a shift from a science-first startup to a company that had to plan, fund and deliver real medicines.
In 2020, co-founder Emmanuelle Charpentier and Jennifer Doudna won the Nobel Prize in Chemistry for CRISPR/Cas9. That same year, the company reported its first clinical data on an experimental CRISPR-edited CAR T therapy, a different use of the same tool. The Nobel was outside validation for the science the company had been built on, delivered while it was still years from an approved product.
The payoff arrived in 2023: regulators in the United States, Great Britain and Bahrain approved CASGEVY, the therapy developed with Vertex, for eligible patients with sickle cell disease or beta thalassemia. It was the world's first approved CRISPR-based medicine. A tool that began as a lab curiosity had become a treatment people could actually receive.
Also in 2023, co-founder Rodger Novak stepped down as President and Chairman. Samarth Kulkarni took over as Chairman while staying CEO, so the founder era gave way to a leader running the whole show.
With CASGEVY on the market, CEO Sam Kulkarni said the company was entering a second phase. More than 500 patients had started treatment, and revenue was expected to grow as they moved through the process. Meanwhile, six assets were expected to produce data within a year or so across heart, autoimmune, cancer and rare disease programs, a push to become more than a one-product company.
The honest picture is a pioneering but unprofitable company. It proved CRISPR can become a real medicine, which is a huge scientific milestone, but turning that into a steady business is the hard part. Competition is rising from other gene-editing players like Beam Therapeutics and from newer, simpler treatments, and the enormous cost and complexity of Casgevy keep it a niche product for now. Investors are essentially betting that the science keeps paying off faster than the cash runs out.
Saved answer · last researched 1 Nov 2026